Alfaxalone

Alfaxalone is a neuroactive steroid that modulates the GABAA receptor, which has shown recent widespread use as a sedative and anesthetic agent in cats, especially in patients being screened for cardiovascular disease. This prospective, partially blinded, randomized experimental study aimed to determine if sedation with alfaxalone would alter the appearance of the cardiac silhouette or pulmonary vasculature on thoracic radiographs or echocardiographic indices of cardiac or pulmonary vascular size. Eleven apparently healthy adult cats were recruited from a research colony. Four‐view thoracic radiographs and an echocardiogram were performed at baseline and following a 5 mg/kg intramuscular dose of alfaxalone. Vertebral heart score (VHS) and cranial and caudal lobar pulmonary vascular measurements were obtained at both time points by two independent blinded observers, and these were analyzed using two‐way ANOVA. The nonblinded echocardiographer obtained echocardiographic measurements at both time points, which were analyzed using a paired t‐test or Wilcoxon signed rank test. No significant differences were identified in VHS measurements or echocardiographic parameters between baseline and sedated cats. In healthy cats, alfaxalone does not appear to significantly affect the cardiovascular structures evaluated via thoracic radiography or echocardiography.

To describe the use of total intravenous anaesthesia (TIVA) in dogs and cats by veterinary anaesthesiologists.

A cross-sectional online, voluntary, anonymous survey.

Data from 153 answered questionnaires.

An anonymous questionnaire was sent via e-mail to diplomates, residents and residency-trained individuals from the American and European Colleges of Veterinary An(a)esthesia and Analgesia, to gather information on the use, perceived advantages, reasons for the use or not of TIVA and attitudes towards this technique in dogs and cats. Descriptive statistics and logistic regression analysis to detect significant associations were performed. The effect size was estimated using the odds ratio (OR) and 95% confidence interval (CI). A significance level of p < 0.05 was used.

We obtained 153/703 responses (66% diplomates, 34% residents; overall response rate of 21.7%). Although 99% and 94% of respondents used TIVA in dogs and cats, respectively, only 14% used it frequently (several times a week) in dogs, and < 1% in cats. Most respondents used propofol (97%, dogs) and alfaxalone (85%, cats), mostly combined with opioids. Reasons for not using TIVA more frequently included prolonged recovery (49%, dogs; 61%, cats), higher cost (46%, dogs) and concerns about drug accumulation (44%, cats). Frequent TIVA use was driven by clinical indications (100%) and greater haemodynamic stability (87%). A higher proportion of respondents using TIVA frequently reported the high stability of the anaesthetic plane (20%; OR = 5.0; 95% CI: 1.4-17.8; p = 0.013) and disagreed with using TIVA only when a specific clinical indication existed (OR = 3.3; 95% CI: 1.4-10.0; p = 0.013).

Although occasional, TIVA use is reported among veterinary anaesthesiologists. Clinical indications for TIVA are the most likely reason for its use, whereas factors such as a prolonged recovery or higher cost might limit its use.